Teijin Limited

Hisao Yamaguchi

Kenichiro Kataoka

Masaichi Hasegawa

Tatsuki Shiota

Takumi Takeyasu

Kenji Hoshina

Hirofumi Tanabe

Mikio Ota

Yasuji Sakuma

Tsutomu Mochizuki

Takashi Kadota

Noboru Yamazaki

Yataro Ichikawa

Yoshiki Suzuki

Yoji Suzuki

Atsushi Imaizumi

Yoshinori Kato

Sachio Ishimoto

Koji Nakagawa

Gentaro Yamashita

Hideki Tsuruta

Takeo Oba

Keiji Komoriya

Kunio Sekine

Hisashi Fukushima

Shoji Ono

Shiro Kondo

Masaharu Kanesaki

Kiyotaka Sunakawa

Hideo Kanno

Yoshiaki Okamiya

Masatoshi Kano

Yoshio Osada

Ikuo Nagata

Masahiro Tsuchimoto

Kenji Ozawa

A pyrrolo[2,3-d]pyrimidine derivative having the general formula [I] ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z have the same definitions as those given in the description, a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical preparation comprising the same, are provided.

Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and

Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group;

2-arylthiazole derivatives and pharmaceutical composition thereof

A benzopyran derivative represented by the formula (I) or its pharmaceutically acceptable salt: ##STR1## wherein either one of X and Y stands for the following formula ##STR2## and the other one of X and Y and R.sup.1 -R.sup.10 stand for various substituents, and ACAT inhibitor, anti-hyperlipidemia agent and anti-atherosclerosis agent compositions containing the same as an active ingredient.

Benzopyran derivative, process for producing the same and pharmaceutical

Pharmaceutical compositions containing a benzoxazole compound and a 2,3-dihydrobenzofuran compound represented by the following formula (I) and its pharmaceutically acceptable salt: ##STR1## In the formula, any one of P, Q, R and S is a group represented by the formula: ##STR2## and R.sub.1, R.sub.2 and the reining three substituents out of the substituents P to S each independently stand for various substituents. These compositions are used as an ATCAT inhibitor or for treating hyperlipidemia and atherosclerosis.

Benzoxa condensed ring compounds, process for producing the same and

Fused pyrimidine derivative, process for preparation of same and

A 1,4-dihydropyridine derivative of the formula ##STR1## wherein R.sup.1 and R.sup.2 are identical or different and each represents a hydrogen atom, a halogen atom or a nitro group, provided that R.sup.1 and R.sup.2 are not hydrogen atoms at the same time; R.sup.3 represents an alkyl group; R.sup.4 represents an aralkyl group which may be substituted; R.sup.5 and R.sup.7 are indentical or different and each represents an alkyl group; R.sup.6 represents a hydrogen atom or an alkyl group; R.sup.8 represents an alkyl group; R.sup.9 represents a hydrogen atom or an alkyl group; n and m are identical or different and each represents an integer of 0 to 6; provided that when either one of R.sup.1 and R.sup.2 is a hydrogen atom, R.sup.9 is an alkyl group; or an acid addition salt thereof. The 1,4-dihydropyridine derivative is characterized by a strong antihypertensive activity and the long duration of the activity.

Certain aralkylaminoalkyl esters of 1,4 dihydropyridines as

A method of culturing microbes which belong to the genus Bordetella characterized by adding cyclodextrin or its derivative to the culture medium used for cultivating microbes belonging to the genus Bordetella and a culture medium therefor.

Culturing Bordetella in media containing etherified cyclodextrin

A pharmaceutical composition for intrarectal administration comprising a pharmaceutically effective amount of an active ingredient which when administered alone to the rectum, is substantially unabsorbable into the living body through the mucous membrane of the rectum, said composition further containing an absorption aid acting within the rectum in such a way as to induce absorption of said active ingredient through the rectal mucous membrane, said absorption aid being characterized by (1) being substantially nontoxic to living organisms, (2) containing in the molecule at least two hydrophilic groups selected from the class consisting of carboxyl groups, acidic hydroxyl groups, carboxyl groups in the form of pharmaceutically acceptable salts, acidic hydroxyl groups in the form of pharmaceutically acceptable salts, carboxyl groups in the form of amides and acidic hydroxyl groups in the form of esters, (3) containing in the molecule at least two lipophilic groups selected from the class consisting of groups of the formulae ##STR1## and -CH.sub.2 -, the number of the lipophilic groups being not less than that of the hydrophilic groups, and (4) having a molecular weight of from about 100 to about 300; and a suppository prepared therefrom in unit dosage form.

Pharmaceutical composition for intrarectal administration, and

Novel substituted hydrazide derivatives of 7-(substituted)amino-3-methylene-cepham-4-carboxylic acids expressed by the formula ##STR1## wherein R.sub.1 represents alkyl containing at least 3 carbon atoms, cycloalkyl, or optionally substituted aryl, and one of R.sub.2 and R.sub.3 represents hydrogen with the other being hydrogen or the same as R.sub.1 ; or R.sub.1 and R.sub.2 form a heterocyclic ring optionally through a hetero atom together with the attached nitrogen and R.sub.3 represents hydrogen atom; and Z.sub.1 represents amino or protected amino; and acid addition salts thereof, which are useful as intermediates for synthesizing cephalosporin antibiotics. These compounds can be prepared in high yields from the corresponding substituted hydrazide derivatives of 6-substituted amino-1-oxide-2, 2-dimethyl-penam-3-carboxylic acids, which are readily available at low costs, by heating them in the presence of a thermal rearrangement promotor such as organic sulfonic acids and optionally in the further presence of a tertiary nitrogen-containing cyclic compound, followed if desired by splitting off the amino-protecting group and converting the product to acid addition salts.

3-Methylene cephalosporanic acid derivatives and process for preparation

Growing community of inventors

Hino, Japan

Hisao Yamaguchi